Physician profile
Jesse W Dunkle
NPI 1811384167
$1,176.58
in general payments reported to CMS, 2019-2025
14 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.52 · 2020: $151 · 2022: $241 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $299.97 | 2025 | Ozempic, Wegovy |
| Viiv Healthcare Company | $241.21 | 2022 | |
| Lilly USA, LLC | $196.27 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $120.56 | 2025 | Evenity |
| Janssen Products, LP | $99.95 | 2020 | |
| Gilead Sciences, INC. | $51.53 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.17 | 2025 | |
| Corcept Therapeutics | $24.47 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.96 | 2025 | Jardiance |
| Antares Pharma, INC. | $21.54 | 2025 | Xyosted |
| Astellas Pharma US INC | $21.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.03 | 2025 | Evkeeza |
| Cranial Technologies, INC | $15.37 | 2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $15.03 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Dunkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.